The prototypical BiTE- blinatumumab (Glaxo-Smith Kline) targets CD3 and CD19 to facilitate T cell-mediated killing of relapsed acute lymphocytic leukemia (ALL) cells [Table 1][109,110]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.